In a recent interview, Dr. Evan Garfein, a leading figure in plastic and reconstructive surgery, shared insights on how 3D printing and tissue-engineered technologies could innovate breast reconstruction. As the head of the Division of Plastic and Reconstructive Surgery at Montefiore Medical Center, Garfein highlighted the advances in reconstructive options available to patients post-mastectomy, which now include both implants and autologous tissue (using the patient’s own skin and fat).
The ultimate aim is to achieve a natural appearance while minimizing recovery times and risks. Despite the reliability of current silicone implants, Dr. Garfein acknowledges potential complications such as infection or implant positioning issues. The advent of bioprinted implants may provide safer, more customized solutions that reduce these risks.
Garfein elaborated on the current landscape of breast reconstruction, pointing out the variety of options that help tailor procedures to individual patient needs, including different shapes and sizes based on body composition. He stressed the importance of offering choices to patients and noted that while some methods are more invasive and risk-laden, they can yield superior aesthetic results.
Looking forward, he envisions a future where bioprinted implants not only eliminate the downsides associated with silicone but also streamline procedures, making them less invasive and less taxing on the body. As the field of breast reconstruction evolves, the goal remains to provide the most natural-looking results while prioritizing patient health and recovery.
For more updates on cancer research and technology, subscribe to CURE®’s newsletters here.